Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
podentamig (MK-4002) / Merck (MSD)
MK-4002-001, NCT04184050 / 2019-004793-26: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 Data from trial for multiple myeloma at ASH 2022 Dec 2022 - Dec 2022: Data from trial for multiple myeloma at ASH 2022 Data from trial for r/r multiple myeloma at ASH 2022 Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022 Data from trial for multiple myeloma at ASH 2021 Dec 2021 - Dec 2021: Data from trial for multiple myeloma at ASH 2021 results for r/r multiple myeloma Dec 2021 - Dec 2021: results for r/r multiple myeloma Data from trial for multiple myeloma Jun 2021 - Jun 2021: Data from trial for multiple myeloma For the treatment of multiple myeloma Jan 2021 - Jan 2021: For the treatment of multiple myeloma Preliminary data from for r/r multiple myeloma Dec 2020 - Dec 2020: Preliminary data from for r/r multiple myeloma More	Active, not recruiting	1	100	Europe, US	MK-4002, HPN217	Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission	06/25	11/25